## Philip Conaghan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4061068/publications.pdf

Version: 2024-02-01

424 papers

21,953 citations

70 h-index

11639

11047 137 g-index

428 all docs

428 docs citations

times ranked

428

17889 citing authors

#	Article	IF	CITATIONS
1	Biopsychosocial Rehabilitation for Inflammatory Arthritis and Osteoarthritis Patients: A Systematic Review and Metaâ€Analysis of Randomized Trials. Arthritis Care and Research, 2023, 75, 423-436.	1.5	5
2	Home-Based Health Care Interventions for People Aged 75 Years and Above With Chronic, Noninflammatory Musculoskeletal Pain: A Scoping Review. Journal of Geriatric Physical Therapy, 2023, 46, 3-14.	0.6	2
3	Bone Marrow Lesions and Magnetic Resonance Imaging–Detected Structural Abnormalities in Patients With Midfoot Pain and Osteoarthritis: A <scp>Crossâ€6ectional</scp> Study. Arthritis Care and Research, 2023, 75, 1113-1122.	1.5	2
4	Impact of osteoarthritis disease severity on treatment patterns and healthcare resource use: analysis of real-world data. Scandinavian Journal of Rheumatology, 2023, 52, 353-363.	0.6	2
5	Secukinumab and Sustained Reduction in Fatigue in Patients With Ankylosing Spondylitis: <scp>Longâ€Term</scp> Results of Two Phase <scp>III</scp> Randomized Controlled Trials. Arthritis Care and Research, 2022, 74, 759-767.	1.5	10
6	Response letter to the Editor. Seminars in Arthritis and Rheumatism, 2022, 52, 151839.	1.6	0
7	Exploring the feasibility, acceptability and value of volunteer peer mentors in supporting self-management of osteoarthritis: a qualitative evaluation. Disability and Rehabilitation, 2022, 44, 6314-6324.	0.9	3
8	Osteoarthritis year in review 2021: epidemiology & therapy. Osteoarthritis and Cartilage, 2022, 30, 196-206.	0.6	159
9	Bone in osteoarthritis: imaging and interventions. Current Opinion in Rheumatology, 2022, 34, 73-78.	2.0	5
10	Burden of chronic low back pain: Association with pain severity and prescription medication use in five large European countries. Pain Practice, 2022, 22, 359-371.	0.9	7
11	Improved Treatment Effect of Triamcinolone Acetonide Extended-Release in Patients with Concordant Baseline Pain Scores on the Average Daily Pain and Western Ontario and McMaster Universities Osteoarthritis Index Pain Scales. Pain and Therapy, 2022, 11, 289-302.	1.5	1
12	Benefit–Risk Analysis of Upadacitinib Compared with Adalimumab in the Treatment of Patients with Moderate-to-Severe Rheumatoid Arthritis. Rheumatology and Therapy, 2022, 9, 191-206.	1.1	4
13	A comparative study of patients presenting for planned and unplanned revision hip or knee arthroplasty. Bone and Joint Journal, 2022, 104-B, 59-67.	1.9	6
14	Implementation of the OMERACT Psoriatic Arthritis Magnetic Resonance Imaging Scoring System in a randomized phase IIb study of abatacept in psoriatic arthritis. Rheumatology, 2022, , .	0.9	2
15	Statin use and MRI subchondral bone marrow lesion worsening in generalized osteoarthritis: longitudinal analysis from Osteoarthritis Initiative data. European Radiology, 2022, 32, 3944-3953.	2.3	6
16	Impact of tanezumab on health status, non-work activities and work productivity in adults with moderate-to-severe osteoarthritis. BMC Musculoskeletal Disorders, 2022, 23, 106.	0.8	2
17	Prediction of flare following remission and treatment withdrawal in early rheumatoid arthritis: post hoc analysis of a phase IIIb trial with abatacept. Arthritis Research and Therapy, 2022, 24, 47.	1.6	7
18	UK poSt Arthroplasty Follow-up rEcommendations (UK SAFE): what does analysis of linked, routinely collected national data sets tell us about mid-late term revision risk after hip replacement? Retrospective cohort study. BMJ Open, 2022, 12, e050877.	0.8	5

#	Article	IF	CITATIONS
19	WOMAC Meaningful Within-patient Change: Results From 3 Studies of Tanezumab in Patients With Moderate-to-severe Osteoarthritis of the Hip or Knee. Journal of Rheumatology, 2022, 49, 615-621.	1.0	8
20	UK poSt Arthroplasty Follow-up rEcommendations (UK SAFE): what does analysis of linked, routinely collected national datasets tell us about mid–late term revision risk after knee replacement?. BMJ Open, 2022, 12, e046900.	0.8	4
21	Symptomatic and structural benefit of cathepsin K inhibition by MIV-711 in a subgroup with unilateral pain: post-hoc analysis of a randomised phase 2a clinical trial Clinical and Experimental Rheumatology, 2022, , .	0.4	1
22	P253â€fUltrasound demonstrates continued improvement in psoriatic arthritis synovitis and enthesitis with secukinumab: 52-week results from a Phase 3 study. Rheumatology, 2022, 61, .	0.9	0
23	Evaluation of two electronic-rehabilitation programmes for persistent knee pain: protocol for a randomised feasibility trial. BMJ Open, 2022, 12, e063608.	0.8	2
24	Effect of zoledronic acid with or without methylprednisolone on 3D bone area and bone shape in patients with symptomatic knee osteoarthritis: A post-hoc analysis of the ZAP2 trial. Seminars in Arthritis and Rheumatism, 2022, 56, 152054.	1.6	0
25	Safety of disinvestment in mid- to late-term follow-up post primary hip and knee replacement: the UK SAFE evidence synthesis and recommendations., 2022, 10, 1-172.		2
26	FDA/Arthritis Foundation osteoarthritis drug development workshop recap: Assessment of long-term benefit. Seminars in Arthritis and Rheumatism, 2022, 56, 152070.	1.6	12
27	Prospects for Therapies in Osteoarthritis. Calcified Tissue International, 2021, 109, 339-350.	1.5	37
28	Bisphosphonates as a treatment modality in osteoarthritis. Bone, 2021, 143, 115352.	1.4	13
29	Reliability and Change in Erosion Measurements by High-resolution Peripheral Quantitative Computed Tomography in a Longitudinal Dataset of Rheumatoid Arthritis Patients. Journal of Rheumatology, 2021, 48, 348-351.	1.0	6
30	Machine-learning, MRI bone shape and important clinical outcomes in osteoarthritis: data from the Osteoarthritis Initiative. Annals of the Rheumatic Diseases, 2021, 80, 502-508.	0.5	56
31	EULAR recommendations for the reporting of ultrasound studies in rheumatic and musculoskeletal diseases (RMDs). Annals of the Rheumatic Diseases, 2021, 80, 840-847.	0.5	31
32	Changes in the pharmacological management of rheumatoid arthritis over two decades. Rheumatology, 2021, 60, 4141-4151.	0.9	17
33	Upadacitinib in Rheumatoid Arthritis: A Benefit–Risk Assessment Across a Phase III Program. Drug Safety, 2021, 44, 515-530.	1.4	28
34	Bâ€eell capacity for differentiation changes with age. Aging Cell, 2021, 20, e13341.	3.0	6
35	The effects of sprifermin on symptoms and structure in a subgroup at risk of progression in the FORWARD knee osteoarthritis trial. Seminars in Arthritis and Rheumatism, 2021, 51, 450-456.	1.6	24
36	Long-term structural and symptomatic effects of intra-articular sprifermin in patients with knee osteoarthritis: 5-year results from the FORWARD study. Annals of the Rheumatic Diseases, 2021, 80, 1062-1069.	0.5	49

#	Article	IF	CITATIONS
37	Individual Participant Symptom Responses to Intra-Articular Lorecivivint in Knee Osteoarthritis: Post Hoc Analysis of a Phase 2B Trial. Rheumatology and Therapy, 2021, 8, 973-985.	1.1	11
38	Volumetric quantitative measurement of hip effusions by manual versus automated artificial intelligence techniques: An OMERACT preliminary validation study. Seminars in Arthritis and Rheumatism, 2021, 51, 623-626.	1.6	6
39	Auto-antibodies to post-translationally modified proteins in osteoarthritis. Osteoarthritis and Cartilage, 2021, 29, 924-933.	0.6	14
40	Harms reported by patients in rheumatology drug trials: a systematic review of randomized trials in the cochrane library from an OMERACT working group. Seminars in Arthritis and Rheumatism, 2021, 51, 607-617.	1.6	3
41	Understanding peer mentorship in supporting selfâ€management of hip and knee osteoarthritis: A qualitative study of mentees' perspectives. Musculoskeletal Care, 2021, , .	0.6	2
42	Peer mentorship to improve self-management of hip and knee osteoarthritis: a randomised feasibility trial. BMJ Open, 2021, 11, e045389.	0.8	5
43	Real world effectiveness and satisfaction with secukinumab in the treatment of patients with psoriatic arthritis: a population survey in five European countries. Current Medical Research and Opinion, 2021, 37, 1845-1853.	0.9	2
44	Arthritis and enthesitis in the hip and pelvis region in spondyloarthritis - OMERACT validation of two whole-body MRI methods. Seminars in Arthritis and Rheumatism, 2021, 51, 940-945.	1.6	6
45	The evolution of instrument selection for inclusion in core outcome sets at OMERACT: Filter 2.2. Seminars in Arthritis and Rheumatism, 2021, 51, 1320-1330.	1.6	25
46	Use and detailed metric properties of patient-reported outcome measures for rheumatoid arthritis: a systematic review covering two decades. RMD Open, 2021, 7, e001707.	1.8	8
47	Cost-effectiveness of hydroxychloroquine versus placebo for hand osteoarthritis: economic evaluation of the HERO trial. F1000Research, 2021, 10, 821.	0.8	2
48	Joint and entheseal inflammation in the knee region in spondyloarthritis - reliability and responsiveness of two OMERACT whole-body MRI scores. Seminars in Arthritis and Rheumatism, 2021, 51, 933-939.	1.6	4
49	Reliability of the Preliminary OMERACT Juvenile Idiopathic Arthritis MRI Score (OMERACT JAMRIS-SIJ). Journal of Clinical Medicine, 2021, 10, 4564.	1.0	6
50	Core outcome measurement instrument selection for physical function in hand osteoarthritis using the OMERACT Filter 2.1 process. Seminars in Arthritis and Rheumatism, 2021, 51, 1311-1319.	1.6	6
51	Improving domain definition and outcome instrument selection: Lessons learned for OMERACT from imaging. Seminars in Arthritis and Rheumatism, 2021, 51, 1125-1133.	1.6	18
52	The design of a randomized, placebo-controlled, dose-ranging trial to investigate the efficacy and safety of the ADAMTS-5 inhibitor S201086/GLPG1972 in knee osteoarthritis. Osteoarthritis and Cartilage Open, 2021, 3, 100209.	0.9	9
53	New developments in osteoarthritis pharmacological therapies. Rheumatology, 2021, 60, vi1-vi11.	0.9	10
54	Single and Composite Endpoints of Within-Patient Improvement in Symptoms: Pooled Tanezumab Data in Patients with Osteoarthritis. Rheumatology and Therapy, 2021, 8, 1759-1774.	1.1	3

#	Article	IF	CITATIONS
55	Pain and Fatigue in Patients With Ankylosing Spondylitis Treated With Tumor Necrosis Factor Inhibitors. Journal of Clinical Rheumatology, 2021, 27, e446-e455.	0.5	12
56	Receptor activator of nuclear factor kappa-Î' ligand (RANKL) serum levels are associated with progression to seropositive/negative rheumatoid arthritis. Clinical and Experimental Rheumatology, 2021, 39, 456-462.	0.4	1
57	Are pain severity and current pharmacotherapies associated with quality of life, work productivity, and healthcare utilisation for people with osteoarthritis in five large European countries?. Clinical and Experimental Rheumatology, 2021, 39, 819-828.	0.4	4
58	Interleukin-7: a potential factor supporting B-cell maturation in the rheumatoid arthritis synovium. Clinical and Experimental Rheumatology, 2021, 39, 253-262.	0.4	0
59	Flexion contracture is associated with knee joint degeneration on magnetic resonance imaging: data from the Osteoarthritis Initiative. Clinical and Experimental Rheumatology, 2021, , .	0.4	1
60	Changes in ankylosing spondylitis incidence, prevalence and time to diagnosis over two decades. RMD Open, 2021, 7, e001888.	1.8	30
61	Interleukin-7: a potential factor supporting B-cell maturation in the rheumatoid arthritis synovium. Clinical and Experimental Rheumatology, 2021, 39, 253-262.	0.4	1
62	Receptor activator of nuclear factor kappa-Î' ligand (RANKL) serum levels are associated with progression to seropositive/negative rheumatoid arthritis. Clinical and Experimental Rheumatology, 2021, 39, 456-462.	0.4	8
63	Precision, Reliability, and Responsiveness of a Novel Automated Quantification Tool for Cartilage Thickness: Data from the Osteoarthritis Initiative. Journal of Rheumatology, 2020, 47, 282-289.	1.0	16
64	Shortâ€Term Recovery Trajectories of Acute Flares in Knee Pain: A UKâ€Netherlands Multicenter Prospective Cohort Analysis. Arthritis Care and Research, 2020, 72, 1687-1692.	1.5	6
65	Baseline Objective Inflammation by Magnetic Resonance Imaging as a Predictor of Therapeutic Benefit in Early Rheumatoid Arthritis With Poor Prognosis. Arthritis Care and Research, 2020, 72, 959-964.	1.5	3
66	Long-term follow-up of patients in the Tight COntrol of inflammation in early Psoriatic Arthritis (TICOPA) trial. Rheumatology, 2020, 59, 807-810.	0.9	8
67	Comparing Psoriatic Arthritis Low-field Magnetic Resonance Imaging, Ultrasound, and Clinical Outcomes: Data from the TICOPA Trial. Journal of Rheumatology, 2020, 47, 1338-1343.	1.0	10
68	Improving Study Conduct and Data Quality in Clinical Trials of Chronic Pain Treatments: IMMPACT Recommendations. Journal of Pain, 2020, 21, 931-942.	0.7	37
69	Investigating the patient acceptable symptom state cut-offs: longitudinal data from a community cohort using the shoulder pain and disability index. Rheumatology International, 2020, 40, 599-605.	1.5	15
70	Time to modify the DAS28 to make it fit for purpose(s) in rheumatoid arthritis?. Expert Review of Clinical Immunology, 2020, $16$ , $1$ -4.	1.3	7
71	The effects of weight loss on imaging outcomes in osteoarthritis of the hip or knee in people who are overweight or obese: a systematic review. Osteoarthritis and Cartilage, 2020, 28, 10-21.	0.6	23
72	O28â€fHas modern UK management of RA led to a reduction in use of steroids and NSAIDs? 20-year data from the clinical practice research datalink. Rheumatology, 2020, 59, .	0.9	0

#	Article	IF	Citations
73	Long-term efficacy and safety of secukinumab in patients with psoriatic arthritis: 5-year (end-of-study) results from the phase 3 FUTURE 2 study. Lancet Rheumatology, The, 2020, 2, e227-e235.	2.2	23
74	Intra-articular Corticosteroid Injections for the Treatment of Hip and Knee Osteoarthritis-related Pain: Considerations and Controversies with a Focus on Imaging—⟨i⟩Radiology⟨/i⟩ Scientific Expert Panel. Radiology, 2020, 297, 503-512.	3 <b>.</b> 6	29
75	MRI of the joint and evaluation of the granulocyte–macrophage colony-stimulating factor–CCL17 axis in patients with rheumatoid arthritis receiving otilimab: a phase 2a randomised mechanistic study. Lancet Rheumatology, The, 2020, 2, e666-e676.	2.2	15
76	A discrete-choice experiment to assess patients' preferences for osteoarthritis treatment: An ESCEO working group. Seminars in Arthritis and Rheumatism, 2020, 50, 859-866.	1.6	7
77	Automated MRI assessment confirms cartilage thickness modification in patients with knee osteoarthritis: post-hoc analysis from a phase II sprifermin study. Osteoarthritis and Cartilage, 2020, 28, 1432-1436.	0.6	11
78	An Update on Imaging in Rheumatoid Arthritis. Current Treatment Options in Rheumatology, 2020, 6, 370-381.	0.6	2
79	Effects of Interleukin- $\hat{\Pi}^2$ Inhibition on Incident Hip and Knee Replacement. Annals of Internal Medicine, 2020, 173, 509-515.	2.0	84
80	Disease-Modifying Effects of a Novel Cathepsin K Inhibitor in Osteoarthritis. Annals of Internal Medicine, 2020, 172, 86.	2.0	92
81	Atlas of the OMERACT Heel Enthesitis MRI Scoring System (HEMRIS). RMD Open, 2020, 6, e001150.	1.8	14
82	Osteoarthritis Preoperative Package for care of Orthotics, Rehabilitation, Topical and oral agent Usage and Nutrition to Improve ouTcomes at a Year (OPPORTUNITY); a feasibility study protocol for a randomised controlled trial. Trials, 2020, 21, 209.	0.7	9
83	T-cell subset abnormalities predict progression along the Inflammatory Arthritis disease continuum:Âimplications for management. Scientific Reports, 2020, 10, 3669.	1.6	20
84	Initiating factors for the onset of OA: A systematic review of animal bone and cartilage pathology in OA. Journal of Orthopaedic Research, 2020, 38, 1810-1818.	1.2	4
85	Adalimumab dose tapering in patients with rheumatoid arthritis who are in long-standing clinical remission: results of the phase IV PREDICTRA study. Annals of the Rheumatic Diseases, 2020, 79, 1023-1030.	0.5	8
86	Towards prevention of post-traumatic osteoarthritis: report from an international expert working group on considerations for the design and conduct of interventional studies following acute knee injury. Osteoarthritis and Cartilage, 2019, 27, 23-33.	0.6	39
87	Update on novel pharmacological therapies for osteoarthritis. Therapeutic Advances in Musculoskeletal Disease, 2019, 11, 1759720X1986449.	1.2	75
88	Determining MRI Inflammation Targets When Considering a Rheumatoid Arthritis Treat-to-Target Strategy: Results of a Randomized, Placebo-Controlled Trial. Advances in Therapy, 2019, 36, 2384-2393.	1.3	3
89	Genetic associations with radiological damage in rheumatoid arthritis: Meta-analysis of seven genome-wide association studies of 2,775 cases. PLoS ONE, 2019, 14, e0223246.	1.1	11
90	Variation in methods, results and reporting in electronic health record-based studies evaluating routine care in gout: A systematic review. PLoS ONE, 2019, 14, e0224272.	1.1	4

#	Article	IF	Citations
91	Very early MRI responses to therapy as a predictor of later radiographic progression in early rheumatoid arthritis. Arthritis Research and Therapy, 2019, 21, 214.	1.6	17
92	152â€ $f$ The OMERACT-OARSI core domain set for measurement in clinical trials of hip and/or knee osteoarthritis. Rheumatology, 2019, 58, .	0.9	4
93	Statin Use and Knee Osteoarthritis Outcome Measures according to the Presence of Heberden Nodes: Results from the Osteoarthritis Initiative. Radiology, 2019, 293, 396-404.	3.6	33
94	Utility of Magnetic Resonance Imaging in Diagnosis and Monitoring Enthesitis in Patients with Spondyloarthritis: An OMERACT Systematic Literature Review. Journal of Rheumatology, 2019, 46, 1207-1214.	1.0	10
95	The OMERACT MRI in Enthesitis Initiative: Definitions of Key Pathologies, Suggested MRI Sequences, and a Novel Heel Enthesitis Scoring System. Journal of Rheumatology, 2019, 46, 1232-1238.	1.0	37
96	Instrument Selection Using the OMERACT Filter 2.1: The OMERACT Methodology. Journal of Rheumatology, 2019, 46, 1028-1035.	1.0	61
97	OMERACT Definitions for Ultrasonographic Pathologies and Elementary Lesions of Rheumatic Disorders 15 Years On. Journal of Rheumatology, 2019, 46, 1388-1393.	1.0	133
98	The OMERACT Core Domain Set for Clinical Trials of Shoulder Disorders. Journal of Rheumatology, 2019, 46, 969-975.	1.0	25
99	The SPECTRA Collaboration OMERACT Working Group: Construct Validity of Joint Space Outcomes with High-resolution Peripheral Quantitative Computed Tomography. Journal of Rheumatology, 2019, 46, 1369-1373.	1.0	15
100	Improving Benefit-harm Assessment of Therapies from the Patient Perspective: OMERACT Premeeting Toward Consensus on Core Sets for Randomized Controlled Trials. Journal of Rheumatology, 2019, 46, 1053-1058.	1.0	8
101	Therapeutic options for targeting inflammatory osteoarthritis pain. Nature Reviews Rheumatology, 2019, 15, 355-363.	3.5	227
102	Rescue Analgesic Medication Use by Patients Treated with Triamcinolone Acetonide Extended-Release for Knee Osteoarthritis Pain: Pooled Analysis of Three Phase 2/3 Randomized Clinical Trials. Pain and Therapy, 2019, 8, 271-280.	1.5	8
103	Safety of Opioids in Osteoarthritis: Outcomes of a Systematic Review and Meta-Analysis. Drugs and Aging, 2019, 36, 129-143.	1.3	57
104	Quantifying circulating Th17 cells by qPCR: potential as diagnostic biomarker for rheumatoid arthritis. Rheumatology, 2019, 58, 2015-2024.	0.9	13
105	Safety of Paracetamol in Osteoarthritis: What Does the Literature Say?. Drugs and Aging, 2019, 36, 7-14.	1.3	59
106	Recommendations for the Reporting of Harms in Manuscripts on Clinical Trials Assessing Osteoarthritis Drugs: A Consensus Statement from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Drugs and Aging, 2019, 36, 145-159.	1.3	15
107	Importance of Safety in the Management of Osteoarthritis and the Need for Updated Meta-Analyses and Recommendations for Reporting of Harms. Drugs and Aging, 2019, 36, 3-6.	1.3	2
108	Developing a Preliminary Definition and Domains of Flare in Knee and Hip Osteoarthritis (OA): Consensus Building of the Flare-in-OA OMERACT Group. Journal of Rheumatology, 2019, 46, 1188-1191.	1.0	23

#	Article	IF	CITATIONS
109	Practical guidance for engaging patients in health research, treatment guidelines and regulatory processes: results of an expert group meeting organized by the World Health Organization (WHO) and the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Aging Clinical and Experimental Research, 2019, 31, 905-915.	1.4	47
110	Improvement in cardiovascular biomarkers sustained at 4 years following an initial treat-to-target strategy in early rheumatoid arthritis. Rheumatology, 2019, 58, 1684-1686.	0.9	3
111	The OMERACT Stepwise Approach to Select and Develop Imaging Outcome Measurement Instruments: The Musculoskeletal Ultrasound Example. Journal of Rheumatology, 2019, 46, 1394-1400.	1.0	30
112	Uptake of the OMERACT-OARSI Hip and Knee Osteoarthritis Core Outcome Set: Review of Randomized Controlled Trials from 1997 to 2017. Journal of Rheumatology, 2019, 46, 976-980.	1.0	25
113	Validity of a two-component imaging-derived disease activity score for improved assessment of synovitis in early rheumatoid arthritis. Rheumatology, 2019, 58, 1400-1409.	0.9	39
114	Corticosteroids and osteoarthritis progression: a confounded issue. Osteoarthritis and Cartilage, 2019, 27, e5-e6.	0.6	7
115	Predicting disease progression and poor outcomes in patients with moderately active rheumatoid arthritis: a systematic review. Rheumatology Advances in Practice, 2019, 3, rkz002.	0.3	9
116	Pain Measurement in Rheumatic and Musculoskeletal Diseases: Where To Go from Here? Report from a Special Interest Group at OMERACT 2018. Journal of Rheumatology, 2019, 46, 1355-1359.	1.0	2
117	Efficacy of Triamcinolone Acetonide Extended-Release in Participants with Unilateral Knee Osteoarthritis: A Post Hoc Analysis. Advances in Therapy, 2019, 36, 1398-1411.	1.3	15
118	Validity and Responsiveness of Combined Inflammation and Combined Joint Damage Scores Based on the OMERACT Rheumatoid Arthritis MRI Scoring System (RAMRIS). Journal of Rheumatology, 2019, 46, 1222-1227.	1.0	8
119	Preliminary Definitions for Sacroiliac Joint Pathologies in the OMERACT Juvenile Idiopathic Arthritis Magnetic Resonance Imaging Score (OMERACT JAMRIS-SIJ). Journal of Rheumatology, 2019, 46, 1192-1197.	1.0	23
120	OMERACT Filter 2.1: Elaboration of the Conceptual Framework for Outcome Measurement in Health Intervention Studies. Journal of Rheumatology, 2019, 46, 1021-1027.	1.0	97
121	Core Domain Set Selection According to OMERACT Filter 2.1: The OMERACT Methodology. Journal of Rheumatology, 2019, 46, 1014-1020.	1.0	65
122	Development and Validation of an OMERACT MRI Whole-Body Score for Inflammation in Peripheral Joints and Entheses in Inflammatory Arthritis (MRI-WIPE). Journal of Rheumatology, 2019, 46, 1215-1221.	1.0	35
123	Implementation and role of modern musculoskeletal imaging in rheumatological practice in member countries of EULAR. RMD Open, 2019, 5, e000950.	1.8	28
124	Towards UK poSt Arthroplasty Follow-up rEcommendations (UK SAFE): protocol for an evaluation of the requirements for arthroplasty follow-up, and the production of consensus-based recommendations. BMJ Open, 2019, 9, e031351.	0.8	7
125	The prevalence and impact of selfâ€reported foot and ankle pain in the over 55 age group: a secondary data analysis from a large community sample. Journal of Foot and Ankle Research, 2019, 12, 53.	0.7	13
126	What Should Be the Primary Target of "Treat to Target―in Psoriatic Arthritis?. Journal of Rheumatology, 2019, 46, 38-42.	1.0	24

#	Article	IF	Citations
127	Longitudinal Reliability of the OMERACT Thumb Base Osteoarthritis Magnetic Resonance Imaging Scoring System (TOMS). Journal of Rheumatology, 2019, 46, 1228-1231.	1.0	4
128	Marked and rapid change of bone shape in acutely ACL injured knees – an exploratory analysis of the Kanon trial. Osteoarthritis and Cartilage, 2019, 27, 638-645.	0.6	31
129	Responsiveness of clinical and ultrasound outcome measures in musculoskeletal systemic lupus erythematosus. Rheumatology, 2019, 58, 1353-1360.	0.9	14
130	Report from the Hand Osteoarthritis Working Group at OMERACT 2018: Update on Core Instrument Set Development. Journal of Rheumatology, 2019, 46, 1183-1187.	1.0	10
131	The OMERACT-OARSI Core Domain Set for Measurement in Clinical Trials of Hip and/or Knee Osteoarthritis. Journal of Rheumatology, 2019, 46, 981-989.	1.0	82
132	A Phase <scp>II</scp> Trial of Lutikizumab, an Anti–Interleukin‶αĴ1² Dual Variable Domain Immunoglobulin, in Knee Osteoarthritis Patients With Synovitis. Arthritis and Rheumatology, 2019, 71, 1056-1069.	2.9	137
133	Patients' preferences for osteoarthritis treatment: the value of stated-preference studies. Aging Clinical and Experimental Research, 2019, 31, 1-3.	1.4	23
134	Defining inflammatory musculoskeletal manifestations in systemic lupus erythematosus. Rheumatology, 2019, 58, 304-312.	0.9	28
135	lmaging in rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, and osteoarthritis: An international viewpoint on the current knowledge and future research priorities. European Journal of Rheumatology, 2019, 6, 37-45.	1.3	9
136	Preliminary Definitions for Sacroiliac Joint Pathologies in the OMERACT Juvenile Idiopathic Arthritis MRI Score (OMERACT JAMRISâ€SIJ). FASEB Journal, 2019, 33, 453.8.	0.2	0
137	Secukinumab provides rapid and persistent relief in pain and fatigue symptoms in patients with ankylosing spondylitis irrespective of baseline C-reactive protein levels or prior tumour necrosis factor inhibitor therapy: 2-year data from the MEASURE 2 study. Clinical and Experimental Rheumatology, 2019, 37, 260-269.	0.4	12
138	Treating osteoarthritis pain: recent approaches using pharmacological therapies. Clinical and Experimental Rheumatology, 2019, 37 Suppl 120, 124-129.	0.4	11
139	Title is missing!. , 2019, 14, e0224272.		0
140	Title is missing!. , 2019, 14, e0224272.		0
141	Title is missing!. , 2019, 14, e0224272.		0
142	Title is missing!. , 2019, 14, e0224272.		0
143	What Imagingâ€Detected Pathologies Are Associated With Shoulder Symptoms and Their Persistence? A Systematic Literature Review. Arthritis Care and Research, 2018, 70, 1169-1184.	1.5	27
144	Design of a phase IV randomised, double-blind, placebo-controlled trial assessing the ImPact ofResidual Inflammation Detected via Imaging TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab inClinical Remission Rheumatoid ArThritis (RA) patients (PREDICTRA). BMJ Open, 2018, 8, e019007.	0.8	7

#	Article	IF	Citations
145	Effects of a Single Intra-Articular Injection of a Microsphere Formulation of Triamcinolone Acetonide on Knee Osteoarthritis Pain. Journal of Bone and Joint Surgery - Series A, 2018, 100, 666-677.	1.4	120
146	Six months' treatment with MIV-711, a novel Cathepsin K inhibitor induces osteoarthritis structure modification: results from a randomized double-blind placebo-controlled phase IIA trial. Osteoarthritis and Cartilage, 2018, 26, S25-S26.	0.6	14
147	Triamcinolone acetonide extended-release injectable suspension (TA-ER) is associated with reduced blood glucose elevation vs. standard triamcinolone in type 2 diabetes mellitus patients with knee osteoarthritis: a randomized, blinded, parallel-group study. Osteoarthritis and Cartilage, 2018, 26, S230.	0.6	3
148	Atlas for the OMERACT thumb base osteoarthritis MRI scoring system (TOMS). RMD Open, 2018, 4, e000583.	1.8	6
149	Bisphosphonates intake and its association with changes of periarticular bone area and three-dimensional shape: data from the Osteoarthritis Initiative (OAI). Osteoarthritis and Cartilage, 2018, 26, 564-568.	0.6	13
150	O12â€fValidity of a2-component imaging-derived disease activity score (2C-DAS28) for improved assessment of synovitis in early rheumatoid arthritis. Rheumatology, 2018, 57, .	0.9	0
151	Utility of ultrasonography in guiding modification of disease modifying antiâ€rheumatic drugs and steroid therapy for inflammatory arthritis in routine clinical practice. International Journal of Rheumatic Diseases, 2018, 21, 155-160.	0.9	11
152	Cognitive Impairment in Rheumatoid Arthritis: A Systematic Review. Arthritis Care and Research, 2018, 70, 39-52.	1.5	95
153	Costâ€Effectiveness of Tight Control of Inflammation in Early Psoriatic Arthritis: Economic Analysis of a Multicenter Randomized Controlled Trial. Arthritis Care and Research, 2018, 70, 462-468.	1.5	12
154	Where does meniscal damage progress most rapidly? An analysis using three-dimensional shape models on data from the Osteoarthritis Initiative. Osteoarthritis and Cartilage, 2018, 26, 62-71.	0.6	14
155	Remission in psoriatic arthritis—where are we now?. Rheumatology, 2018, 57, 1321-1331.	0.9	16
156	Brief Report: A Phase <scp>II</scp> b Trial of a Novel Extendedâ€Release Microsphere Formulation of Triamcinolone Acetonide for Intraarticular Injection in Knee Osteoarthritis. Arthritis and Rheumatology, 2018, 70, 204-211.	2.9	62
157	International patellofemoral osteoarthritis consortium: Consensus statement on the diagnosis, burden, outcome measures, prognosis, risk factors and treatment. Seminars in Arthritis and Rheumatism, 2018, 47, 666-675.	1.6	47
158	Synovial and systemic pharmacokinetics (PK) of triamcinolone acetonide (TA) following intra-articular (IA) injection of an extended-release microsphere-based formulation (FX006) or standard crystalline suspension in patients with knee osteoarthritis (OA). Osteoarthritis and Cartilage, 2018, 26, 34-42.	0.6	99
159	Novel joint selection methods can reduce sample size for rheumatoid arthritis clinical trials with ultrasound endpoints. International Journal of Rheumatic Diseases, 2018, 21, 693-698.	0.9	1
160	A systematic review assessing non-pharmacological conservative treatment studies for people with non-inflammatory multi-joint pain: clinical outcomes and research design considerations. Rheumatology International, 2018, 38, 331-341.	1.5	3
161	Potential Effect Modifiers of the Association Between Physical Activity Patterns and Joint Symptoms in Middleâ€Aged Women. Arthritis Care and Research, 2018, 70, 1012-1021.	1.5	6
162	THU0124â€Low inflammation on magnetic resonance imaging in patients with rheumatoid arthritis that achieved sustained clinical remission on adalimumab: data from the predictra study. , 2018, , .		0

#	Article	IF	CITATIONS
163	Patient-reported outcome measures in osteoarthritis: a systematic search and review of their use and psychometric properties. RMD Open, 2018, 4, e000715.	1.8	22
164	How to be NICEr in treating osteoarthritis. Nature Reviews Rheumatology, 2018, 14, 625-626.	3.5	0
165	$169 \hat{a} \in f$ Secukinumab provides sustained reduction in fatigue in patients with active psoriatic arthritis through three years: long-term data from the FUTURE 1 and FUTURE 2 studies. Rheumatology, 2018, 57, .	0.9	0
166	Triamcinolone acetonide extended-release in patients with osteoarthritis and type 2 diabetes: a randomized, phase 2 study. Rheumatology, 2018, 57, 2235-2241.	0.9	26
167	MRI cartilage thickness and KL grades show different associations with osteoarthritis pain: a study using accurate 3D MRI data from 9592 normal and osteoarthritic knees in the OAI. Osteoarthritis and Cartilage, 2018, 26, S234.	0.6	0
168	Traditional mechanical and patient factors have negligible effects on cartilage thickness outside of oa disease status: a study using accurate 3D MRI data from 9592 normal and osteoarthritic knees. Osteoarthritis and Cartilage, 2018, 26, S438-S439.	0.6	0
169	The relationship between two different measures of osteoarthritis bone pathology, bone marrow lesions and 3D bone shape: data from the osteoarthritis initiative. Osteoarthritis and Cartilage, 2018, 26, S444.	0.6	1
170	Hydroxychloroquine Effectiveness in Reducing Symptoms of Hand Osteoarthritis. Annals of Internal Medicine, 2018, 168, 385.	2.0	63
171	The relationship between accurate 3D measurements of cartilage thickness and radiographic joint space width: data from the osteoarthritis initiative. Osteoarthritis and Cartilage, 2018, 26, S450-S451.	0.6	0
172	Promoting selfâ€management in older people with arthritis: Preliminary findings of the Northern Ireland Staying Connected Programme. Musculoskeletal Care, 2018, 16, 489-493.	0.6	4
173	The relationship between two different measures of osteoarthritis bone pathology, bone marrow lesions and 3D bone shape: data from the Osteoarthritis Initiative. Osteoarthritis and Cartilage, 2018, 26, 1333-1337.	0.6	14
174	$176 \widehat{a} \in f$ Secukinumab provides sustained reduction in fatigue in patients with ankylosing spondylitis through three years: long-term results of two randomised double-blind placebo-controlled phase III studies. Rheumatology, 2018, 57, .	0.9	1
175	Triamcinolone acetonide extended-release injectable suspension (TA-ER) provides clinically relevant improvements in pain and function of knee osteoarthritis: a pooled analysis of 3 randomized clinical trials employing composite assessments. Osteoarthritis and Cartilage, 2018, 26, S232-S233.	0.6	0
176	What is the added value of ultrasound joint examination for monitoring synovitis in rheumatoid arthritis and can it be used to guide treatment decisions? A systematic review and cost-effectiveness analysis. Health Technology Assessment, 2018, 22, 1-258.	1.3	17
177	SAT0671 Initial development of a whole-body magnetic resonance imaging inflammation index for active disease of peripheral joints and entheses in patients with inflammatory arthritis. , 2018, , .		0
178	SP0151â€Does imaging support the vascular nature of osteoarthritis?. , 2018, , .		0
179	SP0062â€How to use mri in the diagnosis and management of osteoarthritis. , 2018, , .		0
180	SAT0667â€Implementation and role of modern musculoskeletal imaging in rheumatological practice in europe. , 2018, , .		0

#	Article	IF	Citations
181	AB0591â€Sle res ponder index (SRI) underestimates clinical response in musculoskeletal systemic lupus erythematosus. , 2018, , .		O
182	FRIO209â€Recommendations for acquisition and considerations for interpretation of mri of the spine and sacroiliac joints in the investigation of axial spondyloarthritis in the uk. , 2018, , .		0
183	FRIOO44â€Exceeding predefined thresholds for mri bone oedema and erosion and haq-di can predict relapse after withdrawal of all treatment in mtx-naÃve patients with ra in remission after 12 months of abatacept therapy in the avert trial. , 2018, , .		0
184	SAT0676â $\in$ Ultrasound detected inflammation in rheumatoid arthritis: elucidating the relationship with clinical manifestations at the wrist., 2018,,.		0
185	AB1175â€Development and preliminary validation of an omeract mri enthesitis scoring system for the ankle in spondyloarthritis. , 2018, , .		0
186	Serum IL-7 as diagnostic biomarker for rheumatoid arthritis, validation with EULAR 2010 classification criteria. Clinical and Experimental Rheumatology, 2018, 36, 115-120.	0.4	12
187	Update on magnetic resonance imaging and ultrasound in rheumatoid arthritis. Clinical and Experimental Rheumatology, 2018, 36 Suppl 114, 16-23.	0.4	6
188	Update on imaging in rheumatic diseases. Clinical and Experimental Rheumatology, 2018, 36 Suppl 114, 2.	0.4	1
189	Synovitis in osteoarthritis: current understanding with therapeutic implications. Arthritis Research and Therapy, 2017, 19, 18.	1.6	615
190	Short-term changes on MRI predict long-term changes on radiography in rheumatoid arthritis: an analysis by an OMERACT Task Force of pooled data from four randomised controlled trials. Annals of the Rheumatic Diseases, 2017, 76, 992-997.	0.5	17
191	Is MRI a predictive biomarker for clinical response to biologics in rheumatoid arthritis?. Annals of the Rheumatic Diseases, 2017, 76, e45-e45.	0.5	3
192	Relationship of patient-reported outcomes with MRI measures in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2017, 76, 486-490.	0.5	38
193	Ultrasound-detected pathologies cluster into groups with different clinical outcomes: data from 3000 community referrals for shoulder pain. Arthritis Research and Therapy, 2017, 19, 30.	1.6	11
194	Development and Validation of the OMERACT Rheumatoid Arthritis Magnetic Resonance Tenosynovitis Scoring System in a Multireader Exercise. Journal of Rheumatology, 2017, 44, 1688-1693.	1.0	23
195	Hydroxychloroquine in hand OA; Results of the UK hero trial. Osteoarthritis and Cartilage, 2017, 25, 53-S4.	0.6	0
196	Whole-body Magnetic Resonance Imaging in Inflammatory Arthritis: Systematic Literature Review and First Steps Toward Standardization and an OMERACT Scoring System. Journal of Rheumatology, 2017, 44, 1699-1705.	1.0	48
197	Development and Reliability of a Preliminary Foot Osteoarthritis Magnetic Resonance Imaging Score. Journal of Rheumatology, 2017, 44, 1257-1264.	1.0	7
198	Obesity and rates of clinical remission and low MRI inflammation in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2017, 76, 1743-1746.	0.5	32

#	Article	IF	Citations
199	The dynamics of response as measured by multiple composite outcome tools in the Tight COntrol of inflammation in early Psoriatic Arthritis (TICOPA) trial. Annals of the Rheumatic Diseases, 2017, 76, 1688-1692.	0.5	17
200	EULAR recommendations for the use of imaging in the clinical management of peripheral joint osteoarthritis. Annals of the Rheumatic Diseases, 2017, 76, 1484-1494.	0.5	170
201	Development and Reliability of the OMERACT Thumb Base Osteoarthritis Magnetic Resonance Imaging Scoring System. Journal of Rheumatology, 2017, 44, 1694-1698.	1.0	27
202	Reducing arthritis pain through physical activity: a new public health, tiered approach. British Journal of General Practice, 2017, 67, 438-439.	0.7	3
203	THU0393â€Secukinumab provides sustained reduction in fatigue in patients with ankylosing spondylitis through 3 years: long-term results of two randomised double-blind placebo-controlled phase 3 studies. , 2017, , .		0
204	Scoring ultrasound synovitis in rheumatoid arthritis: a EULAR-OMERACT ultrasound taskforce-Part 2: reliability and application to multiple joints of a standardised consensus-based scoring system. RMD Open, 2017, 3, e000427.	1.8	149
205	The SPECTRA Collaboration OMERACT Special Interest Group: Current Research and Future Directions. Journal of Rheumatology, 2017, 44, 1911-1915.	1.0	11
206	A new lipid formulation of low dose ibuprofen shows non-inferiority to high dose standard ibuprofen: the FLARE study (flaring arthralgia relief evaluation in episodic flaring knee pain) $\hat{a} \in \hat{a}$ randomised double-blind study. Osteoarthritis and Cartilage, 2017, 25, 1942-1951.	0.6	7
207	OP0107â€Pain still remains a high unmet need among psoriatic arthritis patients receiving existing biologic treatment: results from a multi national real-world survey. , 2017, , .		2
208	Quality of reporting of harms in randomised controlled trials of pharmacological interventions for rheumatoid arthritis: a systematic review. Evidence-Based Medicine, 2017, 22, 170-177.	0.6	17
209	Scoring ultrasound synovitis in rheumatoid arthritis: a EULAR-OMERACT ultrasound taskforce $\langle b \rangle$ Part 1: definition and development of a standardised, consensus-based scoring system. RMD Open, 2017, 3, e000428.	1.8	250
210	Cartilage Thickness, Denudation and Kl Grade: A Study of Medial Femorotibial Joints in 8,890 Knees from the Osteoarthritis Initiative. Osteoarthritis and Cartilage, 2017, 25, S223-S224.	0.6	3
211	3D Knee Bone Shape Predisposes to ACL Rupture: Data from the Osteoarthritis Initiative and the Kanon Study. Osteoarthritis and Cartilage, 2017, 25, S237-S238.	0.6	0
212	A new lipid formulation of low dose (1200 mg) ibuprofen is non-inferior to high dose (2400 mg) standard ibuprofen capsules in managing episodic knee pain flares. Osteoarthritis and Cartilage, 2017, 25, S439-S440.	0.6	0
213	The Relationship Between Synovial Pathobiology and Magnetic Resonance Imaging Abnormalities in Rheumatoid Arthritis: A Systematic Review. Journal of Rheumatology, 2017, 44, 1311-1324.	1.0	11
214	Safety, tolerability and pharmacokinetics of ONO-4474 in healthy subjects: a potential therapy for pain in osteoarthritis. Osteoarthritis and Cartilage, 2017, 25, S174.	0.6	0
215	Clinimetrics of Ultrasonography in Osteoarthritis: A Systematic Literature Review. Osteoarthritis and Cartilage, 2017, 25, S241.	0.6	1
216	Patellofemoral Bone Morphology is Related to Gender But Not Pain: 3D Quantitative Data Analysis From The OAI. Osteoarthritis and Cartilage, 2017, 25, S251-S252.	0.6	1

#	Article	IF	CITATIONS
217	Racial Differences in Magnetic Resonance Image-based Three-dimensional Bone Shape of the Femur Versus the Tibia at the Knee: Data from the Osteoarthritis Initiative. Osteoarthritis and Cartilage, 2017, 25, S296.	0.6	0
218	The OMERACT Rheumatoid Arthritis Magnetic Resonance Imaging (MRI) Scoring System: Updated Recommendations by the OMERACT MRI in Arthritis Working Group. Journal of Rheumatology, 2017, 44, 1706-1712.	1.0	102
219	Engaging Stakeholders and Promoting Uptake of OMERACT Core Outcome Instrument Sets. Journal of Rheumatology, 2017, 44, 1551-1559.	1.0	27
220	The contribution of musculoskeletal disorders in multimorbidity: Implications for practice and policy. Best Practice and Research in Clinical Rheumatology, 2017, 31, 129-144.	1.4	99
221	Effect of bisphosphonate use on trajectories of MRI-based three-dimensional bone shape of the knee over four years. Osteoarthritis and Cartilage, 2017, 25, S58.	0.6	4
222	Psoriatic arthritis: lessons from imaging studies and implications for therapy. Expert Review of Clinical Immunology, 2017, 13, 133-142.	1.3	22
223	Dichotomous versus semi-quantitative scoring of ultrasound joint inflammation in rheumatoid arthritis using novel individualized joint selection methods. Clinical Rheumatology, 2017, 36, 1137-1141.	1.0	3
224	Successful Stepwise Development of Patient Research Partnership: 14 Years' Experience of Actions and Consequences in Outcome Measures in Rheumatology (OMERACT). Patient, 2017, 10, 141-152.	1.1	41
225	THU0175â€Inflammation detected with modern sensitive mri analysis demonstrates that therapeutic response as early as one month predicts 12-month radiographic progression: data from a study using tofacitinib and methotrexate in methotrexate-naÃve patients with early ra., 2017,,.		0
226	02.18â€Can rankl serum levels predict future progression to rheumatoid arthritis in early arthritis clinic patients?. , 2017, , .		0
227	SAT0463â€Secukinumab provides sustained reduction in fatigue in patients with active psoriatic arthritis through 3 years: long-term data from the future 1 and future 2 studies. , 2017, , .		0
228	FRI0630â€Can whole body mri at baseline identify definite inflammatory arthritis patterns in undifferentiated arthritis?., 2017, , .		0
229	OP0164â€Optimizing recruitment criteria for an osteoarthritis structure modification trial: data from the oai. , 2017, , .		0
230	AB0685â€Secukinumab provides sustained improvements in work productivity and health related quality of life in patients with ankylosing spondylitis: long-term results from measure 1 and measure 2., 2017, , .		1
231	SAT0624â€Quantitative 3D imaging of tenosynovitis and bone marrow edema by DCE-MRI is a sensitive measure of response to therapy in rheumatoid arthritis. , 2017, , .		0
232	SAT0666â€Sample size for RA clinical trials using ultrasound outcome measures may be reduced by novel joint selection methods: a pilot study. , 2017, , .		0
233	Patellofemoral morphology is not related to pain using three-dimensional quantitative analysis in an older population: data from the Osteoarthritis Initiative. Rheumatology, 2017, 56, 2135-2144.	0.9	5
234	Development and validation of rheumatoid arthritis magnetic resonance imaging inflammation thresholds associated with lack of damage progression. Clinical and Experimental Rheumatology, 2017, 35, 607-613.	0.4	7

#	Article	IF	CITATIONS
235	The role of ultrasound in assessing musculoskeletal symptoms of systemic lupus erythematosus: a systematic literature review. Rheumatology, 2016, 55, kev343.	0.9	25
236	SAT0421â€Reduction in Fatigue in Patients with Active Ankylosing Spondylitis: Results of Two Phase 3 Studies of Secukinumab. Annals of the Rheumatic Diseases, 2016, 75, 823.1-823.	0.5	1
237	Ms. A.M. Taylor, et al reply. Journal of Rheumatology, 2016, 43, 826.2-827.	1.0	0
238	Does flare trial design affect the effect size of non-steroidal anti-inflammatory drugs in symptomatic osteoarthritis? A systematic review and meta-analysis. Annals of the Rheumatic Diseases, 2016, 75, 1971-1978.	0.5	10
239	Bone Area Provides a Responsive Outcome Measure for Bone Changes in Short-term Knee Osteoarthritis Studies. Journal of Rheumatology, 2016, 43, 2179-2182.	1.0	8
240	THU0442â€Reduction in Fatigue in Patients with Active Psoriatic Arthritis Are Sustained over 2 Years: Long-Term Results of Two Phase 3 Studies with Secukinumab. Annals of the Rheumatic Diseases, 2016, 75, 351.1-351.	0.5	0
241	Targeting ultrasound remission in early rheumatoid arthritis: the results of the TaSER study, a randomised clinical trial. Annals of the Rheumatic Diseases, 2016, 75, 1043-1050.	0.5	167
242	Does sports participation (including level of performance and previous injury) increase risk of osteoarthritis? A systematic review and meta-analysis. British Journal of Sports Medicine, 2016, 50, 1459-1466.	3.1	46
243	Comparing the effects of tofacitinib, methotrexate and the combination, on bone marrow oedema, synovitis and bone erosion in methotrexate-naive, early active rheumatoid arthritis: results of an exploratory randomised MRI study incorporating semiquantitative and quantitative techniques.  Annals of the Rheumatic Diseases, 2016, 75, 1024-1033.	0.5	85
244	Sustained improvements in MRI outcomes with abatacept following the withdrawal of all treatments in patients with early, progressive rheumatoid arthritis. Annals of the Rheumatic Diseases, 2016, 75, 1501-1505.	0.5	17
245	FRI0521â€Reliability of An Omeract Rheumatoid Arthritis Tenosynovitis Scoring System for Wrist and Hand. Annals of the Rheumatic Diseases, 2016, 75, 627.3-628.	0.5	1
246	Harmonising data collection from osteoarthritis studies to enable stratification: recommendations on core data collection from an Arthritis Research UK clinical studies group. Rheumatology, 2016, 55, 1394-1402.	0.9	8
247	Imaging of osteoarthritis (OA): What is new?. Best Practice and Research in Clinical Rheumatology, 2016, 30, 653-669.	1.4	30
248	Agreement between a physiotherapist and an orthopaedic surgeon regarding management and prescription of corticosteroid injection for patients with shoulder pain. Manual Therapy, 2016, 26, 216-222.	1.6	14
249	Mesenchymal Stem Cell Alterations in Bone Marrow Lesions in Patients With Hip Osteoarthritis. Arthritis and Rheumatology, 2016, 68, 1648-1659.	2.9	94
250	Synovial incorporation of polyacrylamide hydrogel after injection into normal and osteoarthritic animal joints. Osteoarthritis and Cartilage, 2016, 24, 1999-2002.	0.6	14
251	Improvement in insulin resistance is greater when infliximab is added to methotrexate during intensive treatment of early rheumatoid arthritis—results from the IDEA study. Rheumatology, 2016, 55, 2181-2190.	0.9	21
252	Osteoarthritis. Nature Reviews Disease Primers, 2016, 2, 16072.	18.1	1,011

#	Article	IF	CITATIONS
253	Knee Pain Predicts Subsequent Shoulder Pain and the Association Is Mediated by Leg Weakness: Longitudinal Observational Data from the Osteoarthritis Initiative. Journal of Rheumatology, 2016, 43, 2049-2055.	1.0	8
254	The relationship between three-dimensional knee MRI bone shape and total knee replacement—a case control study: data from the Osteoarthritis Initiative. Rheumatology, 2016, 55, 1585-1593.	0.9	41
255	AB0982â€Dichotomous Scoring of Ra Ultrasound Inflammation Demonstrates Good Responsiveness Compared To Semi-Quantitative Scoring When Using Novel Joint Selection Methods: Table 1 Annals of the Rheumatic Diseases, 2016, 75, 1237.1-1237.	0.5	0
256	THU0411â€Fatigue in Patients with Ankylosing Spondylitis and Low Vitality in Those with Psoriatic Arthritis: Results from A Large Real-World Survey in Europe and The USA. Annals of the Rheumatic Diseases, 2016, 75, 337.2-337.	0.5	0
257	OP0118â€Development of The Eular Recommendations for The Use of Imaging in The Clinical Management of Osteoarthritis. Annals of the Rheumatic Diseases, 2016, 75, 100.1-100.	0.5	0
258	THU0630â€Treatment Failure, Treatment Switching and Health-Related Quality of Life in Patients with Ankylosing Spondylitis or Psoriatic Arthritis: Results from A Large Multinational Real-World Sample in Europe and The USA. Annals of the Rheumatic Diseases, 2016, 75, 421.2-422.	0.5	0
259	A5.01â€The relationship between total knee replacement and 3D MRI knee bone shape: Data from the osteoarthritis initiative. Annals of the Rheumatic Diseases, 2016, 75, A41.2-A41.	0.5	0
260	Satisfaction, Adherence and Health-Related Quality of Life with Transdermal Buprenorphine Compared with Oral Opioid Medications in the Usual Care of Osteoarthritis Pain. Patient, 2016, 9, 359-371.	1.1	8
261	The clinical characteristics of older people with chronic multiple-site joint pains and their utilisation of therapeutic interventions: data from a prospective cohort study. BMC Musculoskeletal Disorders, 2016, 17, 194.	0.8	20
262	Brief Report: Secukinumab Provides Significant and Sustained Inhibition of Joint Structural Damage in a Phase III Study of Active Psoriatic Arthritis. Arthritis and Rheumatology, 2016, 68, 1914-1921.	2.9	64
263	Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: a multicentre, randomised, double-blind, non-inferiority trial versus celecoxib. Annals of the Rheumatic Diseases, 2016, 75, 37-44.	0.5	194
264	Ultrasound findings predict progression to inflammatory arthritis in anti-CCP antibody-positive patients without clinical synovitis. Annals of the Rheumatic Diseases, 2016, 75, 2060-2067.	0.5	99
265	Novel Ultrasound Joint Selection Methods Using a Reduced Joint Number Demonstrate Inflammatory Improvement when Compared to Existing Methods and Disease Activity Score at 28 Joints. Journal of Rheumatology, 2016, 43, 34-37.	1.0	8
266	Osteoarthritic bone marrow lesions almost exclusively colocate with denuded cartilage: a 3D study using data from the Osteoarthritis Initiative. Annals of the Rheumatic Diseases, 2016, 75, 1852-1857.	0.5	30
267	Which patellofemoral joint imaging features are associated with patellofemoral pain? Systematic review and meta-analysis. Osteoarthritis and Cartilage, 2016, 24, 224-236.	0.6	43
268	Validity of early MRI structural damage end points and potential impact on clinical trial design in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2016, 75, 1114-1119.	0.5	25
269	Recommendations for the conduct of efficacy trials of treatment devices for osteoarthritis: a report from a working group of the Arthritis Research UK Osteoarthritis and Crystal Diseases Clinical Studies Group: Box 1. Rheumatology, 2016, 55, 320-326.	0.9	15
270	NSAIDs or paracetamol for short-term treatment of mild to moderate knee pain in early osteoarthritis: are they equivalent?. Evidence-Based Medicine, 2016, 21, 14-14.	0.6	3

#	Article	IF	CITATIONS
271	The prevalence, impact and management of musculoskeletal disorders in older people living in care homes: a systematic review. Rheumatology International, 2016, 36, 55-64.	1.5	18
272	Paracetamol: not as safe as we thought? A systematic literature review of observational studies. Annals of the Rheumatic Diseases, 2016, 75, 552-559.	0.5	313
273	FRIO513â€Validating Mri-Detected Inflammation Thresholds Predictive of Structural Damage Progression in Patients with Rheumatoid Arthritis in A Randomized Placebo-Controlled Trial. Annals of the Rheumatic Diseases, 2016, 75, 624.2-624.	0.5	3
274	Increasing Capacity for the Treatment of Common Musculoskeletal Problems: A Non-Inferiority RCT and Economic Analysis of Corticosteroid Injection for Shoulder Pain Comparing a Physiotherapist and Orthopaedic Surgeon. PLoS ONE, 2016, 11, e0162679.	1.1	12
275	Improving joint pain and function in osteoarthritis. Practitioner, 2016, 260, 17-20.	0.3	5
276	THUO425â€Secukinumab Improves Signs and Symptoms of Active Psoriatic Arthritis in a Phase 3 Randomized, Multicenter, Double-Blind, Placebo-Controlled Study Using a Subcutaneous Dosing Regimen (Future 2). Annals of the Rheumatic Diseases, 2015, 74, 352.3-353.	0.5	1
277	FRIO552â€Why Does Joint Pain "Spreadâ€? Knee Pain Predicts Later Shoulder Pain, Due to Muscle Weakness Data from the Osteoarthritis Initiative. Annals of the Rheumatic Diseases, 2015, 74, 627.3-628.	0.5	O
278	SAT0222â€Effects of Tofacitinib on MRI Endpoints in Methotrexate-Naive Early Rheumatoid Arthritis: A Phase 2 MRI Study with Semi-Quantitative and Quantitative Endpoints. Annals of the Rheumatic Diseases, 2015, 74, 738-738.	0.5	4
279	THU0414â€Secukinumab Inhibits Radiographic Progression in Patients with Psoriatic Arthritis: Data from a Phase 3 Randomized, Multicenter, Double-Blind, Placebo-Controlled Study (Future 1). Annals of the Rheumatic Diseases, 2015, 74, 347.2-348.	0.5	2
280	FRIO5O3â€Eular-Pres Points to Consider for the Use of Imaging in the Diagnosis and Management of Juvenile Idiopathic Arthritis in Clinical Practice. Annals of the Rheumatic Diseases, 2015, 74, 611.1-611.	0.5	0
281	FRIO569â€The Role of Musculoskeletal Ultrasound in the Stratification of SLE; A Multicenter Cross-Sectional Study: Table 1 Annals of the Rheumatic Diseases, 2015, 74, 633.3-634.	0.5	1
282	SP0098â€What is New:Osteoarthritis. Annals of the Rheumatic Diseases, 2015, 74, 25.3-25.	0.5	0
283	THU0498â€The Patients' Experience of Imaging: Views from a Group Convened to Support the Development of Points to Consider for the Use of Imaging in the Diagnosis and Management of Juvenile Idiopathic Arthritis. Annals of the Rheumatic Diseases, 2015, 74, 380.2-380.	0.5	O
284	SATO601â€A Novel, Fully 3-Dimensional Dynamic Contrast MRI Method in the Hand Reveals Details of Synovial Inflammation and Provides a Sensitive Measure of Change. Annals of the Rheumatic Diseases, 2015, 74, 879.1-879.	0.5	0
285	SAT0585â€Can we Stop Using Contrast in RA MRI Clinical Trials? Quantitative MRI Demonstrates Similar Responsiveness for Contrast and Contrast-Free Synovitis Assessment. Annals of the Rheumatic Diseases, 2015, 74, 873.1-873.	0.5	O
286	THUO426â€Ultrasound Identifies Additional Erosive Disease in Patients with Early Psoriatic Arthritis – Results from the Ticopa Study:. Annals of the Rheumatic Diseases, 2015, 74, 353.1-353.	0.5	1
287	Inadequate pain relief and large functional loss among patients with knee osteoarthritis: evidence from a prospective multinational longitudinal study of osteoarthritis real-world therapies. Rheumatology, 2015, 54, 270-277.	0.9	97
288	Validation of the OMERACT Magnetic Resonance Imaging Joint Space Narrowing Score for the Wrist in a Multireader Longitudinal Trial. Journal of Rheumatology, 2015, 42, 2480-2485.	1.0	27

#	Article	IF	CITATIONS
289	The OMERACT MRI in Arthritis Working Group — Update on Status and Future Research Priorities. Journal of Rheumatology, 2015, 42, 2470-2472.	1.0	18
290	Are guidelines good value for money?: Fig. 1. Rheumatology, 2015, 54, kev308.	0.9	0
291	Validation of the OMERACT Psoriatic Arthritis Magnetic Resonance Imaging Score (PsAMRIS) for the Hand and Foot in a Randomized Placebo-controlled Trial. Journal of Rheumatology, 2015, 42, 2473-2479.	1.0	54
292	Ultrasound assessment of response to intra-articular therapy in osteoarthritis of the knee. Rheumatology, 2015, 54, 1385-1391.	0.9	27
293	Raising the quality of rheumatology management recommendations: lessons from the EULAR process 10 years after provision of standard operating procedures. Rheumatology, 2015, 54, 1392-1396.	0.9	5
294	Changes in peripheral blood immune cell composition inÂosteoarthritis. Osteoarthritis and Cartilage, 2015, 23, 1870-1878.	0.6	54
295	Harmonizing Pain Outcome Measures: Results of the Pre-OMERACT Meeting on Partnerships for Consensus on Patient-important Pain Outcome Domains Between the Cochrane Musculoskeletal Group and OMERACT. Journal of Rheumatology, 2015, 42, 1943-1946.	1.0	8
296	Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, The, 2015, 386, 1137-1146.	6.3	722
297	Response to: †Paracetamol: is all the concern valid?' by Schwarz and Mullins. Annals of the Rheumatic Diseases, 2015, 74, e49-e49.	0.5	2
298	Pain reduction with oral methotrexate in knee osteoarthritis, a pragmatic phase iii trial of treatment effectiveness (PROMOTE): study protocol for a randomized controlled trial. Trials, 2015, 16, 77.	0.7	30
299	A novel method for bone area measurement provides new insights into osteoarthritis and its progression. Annals of the Rheumatic Diseases, 2015, 74, 519-525.	0.5	74
300	Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial. Lancet, The, 2015, 386, 2489-2498.	6.3	389
301	Is Chronic Pain a Disease in Its Own Right? Discussions from a Pre-OMERACT 2014 Workshop on Chronic Pain. Journal of Rheumatology, 2015, 42, 1947-1953.	1.0	20
302	A systematic review of the relationship between subchondral bone features, pain and structural pathology in peripheral joint osteoarthritis. Arthritis Research and Therapy, 2015, 17, 228.	1.6	136
303	Clinical and radiographic outcomes at 2â€years and the effect of tocilizumab discontinuation following sustained remission in the second and third year of the ACT-RAY study. Annals of the Rheumatic Diseases, 2015, 74, 35-43.	0.5	94
304	The Longitudinal Reliability and Responsiveness of the OMERACT Hand Osteoarthritis Magnetic Resonance Imaging Scoring System (HOAMRIS). Journal of Rheumatology, 2015, 42, 2486-2491.	1.0	25
305	Introduction. Journal of Rheumatology, 2015, 42, 1926-1930.	1.0	0
306	Report from the OMERACT Hand Osteoarthritis Working Group: Set of Core Domains and Preliminary Set of Instruments for Use in Clinical Trials and Observational Studies. Journal of Rheumatology, 2015, 42, 2190-2197.	1.0	62

#	Article	IF	CITATIONS
307	Dialogue on Developing Consensus on Measurement and Presentation of Patient-important Outcomes, Using Pain Outcomes as an Exemplar, in Systematic Reviews: A Preconference Meeting at OMERACT 12. Journal of Rheumatology, 2015, 42, 1931-1933.	1.0	9
308	Current State of Reporting Pain Outcomes in Cochrane Reviews of Chronic Musculoskeletal Pain Conditions and Considerations for an OMERACT Research Agenda. Journal of Rheumatology, 2015, 42, 1934-1942.	1.0	7
309	Monitoring in established RA: Role of imaging and soluble biomarkers. Best Practice and Research in Clinical Rheumatology, 2015, 29, 566-579.	1.4	22
310	The specificity of ultrasound-detected bone erosions for rheumatoid arthritis. Annals of the Rheumatic Diseases, 2015, 74, 897-903.	0.5	83
311	Impact and therapy of osteoarthritis: the Arthritis Care OA Nation 2012 survey. Clinical Rheumatology, 2015, 34, 1581-1588.	1.0	74
312	Biological Therapies in Osteoarthritis. Current Pharmaceutical Design, 2015, 21, 2206-2215.	0.9	14
313	Imaging of osteoarthritis., 2015, , 1483-1491.		0
314	Comparative clinical utility of once-weekly subcutaneous abatacept in the management of rheumatoid arthritis. Therapeutics and Clinical Risk Management, 2014, 10, 313.	0.9	5
315	Update on the OMERACT Magnetic Resonance Imaging Task Force: Research and Future Directions. Journal of Rheumatology, 2014, 41, 383-385.	1.0	3
316	The relationship between clinical characteristics, radiographic osteoarthritis and 3D bone area: data from the Osteoarthritis Initiative. Osteoarthritis and Cartilage, 2014, 22, 1703-1709.	0.6	18
317	Osteoarthritis: recent advances in diagnosis and management. The Prescriber, 2014, 25, 26-34.	0.1	1
318	Greater body mass independently predicts less radiographic progression on X-ray and MRI over $1\hat{a}\in$ "2 $\hat{a}\in$ years. Annals of the Rheumatic Diseases, 2014, 73, 1923-1928.	0.5	78
319	Is There Subclinical Synovitis in Early Psoriatic Arthritis? A Clinical Comparison With Grayâ€6cale and Power Doppler Ultrasound. Arthritis Care and Research, 2014, 66, 432-439.	1.5	79
320	Responsiveness in Rheumatoid Arthritis. A Report from the OMERACT 11 Ultrasound Workshop. Journal of Rheumatology, 2014, 41, 379-382.	1.0	41
321	Drug-free gel containing ultra-deformable phospholipid vesicles (TDT 064) as topical therapy for the treatment of pain associated with osteoarthritis: a review of clinical efficacy and safety. Current Medical Research and Opinion, 2014, 30, 599-611.	0.9	11
322	Acupuncture for Chronic Knee Pain. JAMA - Journal of the American Medical Association, 2014, 312, 1313.	3.8	213
323	Developing Core Outcome Measurement Sets for Clinical Trials: OMERACT Filter 2.0. Journal of Clinical Epidemiology, 2014, 67, 745-753.	2.4	625
324	Osteoarthritis in Europe: impact on health status, work productivity and use of pharmacotherapies in five European countries. Rheumatology, 2014, 53, 937-947.	0.9	134

#	Article	IF	CITATIONS
325	Attitudes of people with osteoarthritis towards their conservative management: a systematic review and meta-ethnography. Rheumatology International, 2014, 34, 299-313.	1.5	43
326	Development and Validation of Modified Disease Activity Scores in Rheumatoid Arthritis: Superior Correlation With Magnetic Resonance Imaging–Detected Synovitis and Radiographic Progression. Arthritis and Rheumatology, 2014, 66, 794-802.	2.9	52
327	Primary care approaches to musculoskeletal multiple-site joint pain pharmacological therapy: a survey of general practitioners. Primary Health Care Research and Development, 2014, 15, 476-481.	0.5	5
328	Early MRI measures independently predict 1-year and 2-year radiographic progression in rheumatoid arthritis: secondary analysis from a large clinical trial. Annals of the Rheumatic Diseases, 2014, 73, 1968-1974.	0.5	75
329	Determining a Magnetic Resonance Imaging Inflammatory Activity Acceptable State Without Subsequent Radiographic Progression in Rheumatoid Arthritis: Results from a Followup MRI Study of 254 Patients in Clinical Remission or Low Disease Activity. Journal of Rheumatology, 2014, 41, 398-406.	1.0	71
330	An immunological biomarker to predict MTX response in early RA. Annals of the Rheumatic Diseases, 2014, 73, 2047-2053.	0.5	51
331	The OMERACT-RAMRIS Rheumatoid Arthritis Magnetic Resonance Imaging Joint Space Narrowing Score: Intrareader and Interreader Reliability and Agreement with Computed Tomography and Conventional Radiography. Journal of Rheumatology, 2014, 41, 392-397.	1.0	38
332	The effects of tocilizumab on osteitis, synovitis and erosion progression in rheumatoid arthritis: results from the ACT-RAY MRI substudy. Annals of the Rheumatic Diseases, 2014, 73, 810-816.	0.5	44
333	Osteoarthritis research priorities: a report from a EULAR ad hoc expert committee. Annals of the Rheumatic Diseases, 2014, 73, 1442-1445.	0.5	120
334	Updating the OMERACT Filter: Implications for Imaging and Soluble Biomarkers. Journal of Rheumatology, 2014, 41, 1016-1024.	1.0	14
335	1.63â€IL-7 drives the tissue architecture of the RA synovium providing a niche for B-cells to mature. Annals of the Rheumatic Diseases, 2014, 73, A27.2-A28.	0.5	0
336	Hydroxychloroquine effectiveness in reducing symptoms of hand osteoarthritis (HERO): study protocol for a randomized controlled trial. Trials, 2013, 14, 64.	0.7	26
337	The TICOPA protocol (Tight COntrol of Psoriatic Arthritis): a randomised controlled trial to compare intensive management versus standard care in early psoriatic arthritis. BMC Musculoskeletal Disorders, 2013, 14, 101.	0.8	89
338	Parallel evolution of OA phenotypes and therapies. Nature Reviews Rheumatology, 2013, 9, 68-70.	3.5	45
339	A multicentre, randomized, placebo- and active-controlled trial comparing the efficacy and safety of topical ketoprofen in Transfersome gel (IDEA-033) with ketoprofen-free vehicle (TDT 064) and oral celecoxib for knee pain associated with osteoarthritis. Rheumatology, 2013, 52, 1303-1312.	0.9	57
340	EULAR recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritis. Annals of the Rheumatic Diseases, 2013, 72, 804-814.	0.5	504
341	Review: The Utility of Magnetic Resonance Imaging for Assessing Structural Damage in Randomized Controlled Trials in Rheumatoid Arthritis. Arthritis and Rheumatism, 2013, 65, 2513-2523.	6.7	40
342	EULAR recommendations for the non-pharmacological core management of hip and knee osteoarthritis. Annals of the Rheumatic Diseases, 2013, 72, 1125-1135.	0.5	1,033

#	Article	IF	Citations
343	Steroid injection and regular shoulder-specific exercises reduce the need for surgery in subacromial impingement syndrome. Evidence-Based Medicine, 2013, 18, e3-e3.	0.6	3
344	The ability of synovitis to predict structural damage in rheumatoid arthritis: a comparative study between clinical examination and ultrasound. Annals of the Rheumatic Diseases, 2013, 72, 665-671.	0.5	110
345	Autoantibodies to Posttranslationally Modified Type II Collagen as Potential Biomarkers for Rheumatoid Arthritis. Arthritis and Rheumatism, 2013, 65, 1702-1712.	6.7	59
346	Impact of intravenous abatacept on synovitis, osteitis and structural damage in patients with rheumatoid arthritis and an inadequate response to methotrexate: the ASSET randomised controlled trial. Annals of the Rheumatic Diseases, 2013, 72, 1287-1294.	0.5	47
347	Methotrexate for pain relief in knee osteoarthritis: an open-label study. Rheumatology, 2013, 52, 888-892.	0.9	50
348	MRI comes of age in RA clinical trials. Annals of the Rheumatic Diseases, 2013, 72, 794-796.	0.5	37
349	THU0016â€Investigation of RA genetic susceptibility loci contribution to response outcomes following conventional DMARD treatment in early RA. Annals of the Rheumatic Diseases, 2013, 71, 159.1-159.	0.5	0
350	SAT0005â€RA genetic susceptibility loci are associated with baseline radiographic joint damage in early RA. Annals of the Rheumatic Diseases, 2013, 71, 472.2-472.	0.5	0
351	How do people with knee osteoarthritis use osteoarthritis pain medications and does this change over time? Data from the Osteoarthritis Initiative. Arthritis Research and Therapy, 2013, 15, R106.	1.6	66
352	A Home Exercise Programme Is No More Beneficial than Advice and Education for People with Neurogenic Claudication: Results from a Randomised Controlled Trial. PLoS ONE, 2013, 8, e72878.	1.1	18
353	THU0093â€Clinical, radiographic, and immunogenic effects after 1 year of tocilizumab (TCZ)-based treatment strategy with and without methotrexate (MTX) in RA: The act-ray study. Annals of the Rheumatic Diseases, 2013, 71, 185.1-185.	0.5	6
354	Can flare be predicted in DMARD treated RA patients in remission, and is it important? A cohort study. Annals of the Rheumatic Diseases, 2012, 71, 1316-1321.	0.5	160
355	Does joint position affect US findings in inflammatory arthritis?. Rheumatology, 2012, 51, 921-925.	0.9	20
356	A randomized, double-blind, placebo-controlled trial of low-dose oral prednisolone for treating painful hand osteoarthritis. Rheumatology, 2012, 51, 2286-2294.	0.9	62
357	Is there subclinical enthesitis in early psoriatic arthritis? A clinical comparison with power doppler ultrasound. Arthritis Care and Research, 2012, 64, 1617-1621.	1.5	70
358	A turbulent decade for NSAIDs: update on current concepts of classification, epidemiology, comparative efficacy, and toxicity. Rheumatology International, 2012, 32, 1491-1502.	1.5	301
359	Response to Letter to the Editor: "Transdermal buprenorphine plus oral paracetamol vs an oral codeine–paracetamol combination for osteoarthritis of hip and/or knee: a randomised trial. Comments on the article by Conaghan etÂal.― Osteoarthritis and Cartilage, 2012, 20, 337-338.	0.6	0
360	Relationship between early bone mineral density changes and longâ€term function and radiographic progression in rheumatoid arthritis. Arthritis Care and Research, 2012, 64, 66-70.	1.5	19

#	Article	IF	CITATIONS
361	Do non-steroidal anti-inflammatory drugs have a significant effect on detection and grading of ultrasound-detected synovitis in patients with rheumatoid arthritis? Results from a randomised study. Annals of the Rheumatic Diseases, 2011, 70, 1746-1751.	0.5	29
362	A Systematic Literature Review Analysis of Ultrasound Joint Count and Scoring Systems to Assess Synovitis in Rheumatoid Arthritis According to the OMERACT Filter. Journal of Rheumatology, 2011, 38, 2055-2062.	1.0	188
363	The OMERACT Ultrasound Task Force — Status and Perspectives. Journal of Rheumatology, 2011, 38, 2063-2067.	1.0	111
364	Systematic review of the concurrent and predictive validity of MRI biomarkers in OA. Osteoarthritis and Cartilage, 2011, 19, 557-588.	0.6	174
365	Summary and recommendations of the OARSI FDA osteoarthritis Assessment of Structural Change Working Group. Osteoarthritis and Cartilage, 2011, 19, 606-610.	0.6	156
366	Transdermal buprenorphine plus oral paracetamol vs an oral codeine-paracetamol combination for osteoarthritis of hip and/or knee: a randomised trial. Osteoarthritis and Cartilage, 2011, 19, 930-938.	0.6	40
367	Corrigendum to Evolution of semi-quantitative whole joint assessment of knee OA: MOAKS (MRI) Tj ETQq1 1 0.76 Cartilage, 2011, 19, 1168.	84314 rgB 0.6	T /Overlock 9
368	Imaging in rheumatoid arthritis. Best Practice and Research in Clinical Rheumatology, 2011, 25, 569-584.	1.4	44
369	Predicting outcomes in rheumatoid arthritis. Clinical Rheumatology, 2011, 30, 41-47.	1.0	16
370	Extremity magnetic resonance imaging in rheumatoid arthritis: Updated literature review. Arthritis Care and Research, 2011, 63, 660-665.	1.5	14
371	The effects of golimumab on radiographic progression in rheumatoid arthritis: Results of randomized controlled studies of golimumab before methotrexate therapy and golimumab after methotrexate therapy. Arthritis and Rheumatism, 2011, 63, 1200-1210.	6.7	104
372	Significant improvement in synovitis, osteitis, and bone erosion following golimumab and methotrexate combination therapy as compared with methotrexate alone: A magnetic resonance imaging study of 318 methotrexate-naive rheumatoid arthritis patients. Arthritis and Rheumatism, 2011, 63, 3712-3722.	6.7	79
373	Synovitis and Osteitis Are Very Frequent in Rheumatoid Arthritis Clinical Remission: Results from an MRI Study of 294 Patients in Clinical Remission or Low Disease Activity State. Journal of Rheumatology, 2011, 38, 2039-2044.	1.0	101
374	Exploratory analyses of the association of MRI with clinical, laboratory and radiographic findings in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 2011, 70, 2126-2130.	0.5	32
375	Update on Research and Future Directions of the OMERACT MRI Inflammatory Arthritis Group. Journal of Rheumatology, 2011, 38, 2031-2033.	1.0	14
376	Systematic Review of MRI, Ultrasound, and Scintigraphy as Outcome Measures for Structural Pathology in Interventional Therapeutic Studies of Knee Arthritis: Focus on Responsiveness. Journal of Rheumatology, 2011, 38, 142-154.	1.0	26
377	Assessment by MRI of inflammation and damage in rheumatoid arthritis patients with methotrexate inadequate response receiving golimumab: results of the GO-FORWARD trial. Annals of the Rheumatic Diseases, 2011, 70, 1968-1974.	0.5	56
378	Reduced IL-7 serum titres are associated with progression towards rheumatoid arthritis in less than 6 months inflammatory arthritis. Annals of the Rheumatic Diseases, 2011, 70, A2-A2.	0.5	0

#	Article	IF	Citations
379	Should imaging be a component of rheumatoid arthritis remission criteria? A comparison between traditional and modified composite remission scores and imaging assessments. Annals of the Rheumatic Diseases, 2011, 70, 792-798.	0.5	185
380	Development and Preliminary Validation of a Magnetic Resonance Imaging Joint Space Narrowing Score for Use in Rheumatoid Arthritis: Potential Adjunct to the OMERACT RA MRI Scoring System. Journal of Rheumatology, 2011, 38, 2045-2050.	1.0	72
381	The OMERACT Psoriatic Arthritis Magnetic Resonance Imaging Score (PsAMRIS) Is Reliable and Sensitive to Change: Results from an OMERACT Workshop. Journal of Rheumatology, 2011, 38, 2034-2038.	1.0	66
382	014 A COMPOSITE SCORE OFMULTI-JOINT RADIOGRAPHIC OSTEOARTHRITIS: THE JOHNSTON COUNTY OSTEOARTHRITIS PROJECT. Osteoarthritis and Cartilage, 2010, 18, S15.	0.6	0
383	021 RESPONSIVENESS AND RELIABILITY OF MRI IN OSTEOARTHRITIS: ANALYTIC LITERATURE REVIEW. Osteoarthritis and Cartilage, 2010, 18, S17-S18.	0.6	3
384	397 DEFINITION OF OSTEOARTHRITIS ON MRI: RESULTS OF A DELPHI EXERCISE. Osteoarthritis and Cartilage, 2010, 18, S174-S175.	0.6	1
385	432 DISTRIBUTION OF BONE MARROW LESIONS IS CLOSELY RELATED TO DENUDED CARTILAGE IN OSTEOARTHRITIS SUBJECTS. Osteoarthritis and Cartilage, 2010, 18, S192-S193.	0.6	0
386	Reduced interleukin 7 serum titres are associated with progression towards rheumatoid arthritis in very early inflammatory arthritis. Annals of the Rheumatic Diseases, 2010, 69, A68-A69.	0.5	0
387	Benefits 8 years after a remission induction regime with an infliximab and methotrexate combination in early rheumatoid arthritis. Rheumatology, 2010, 49, 1971-1974.	0.9	46
388	Persistently moderate DAS-28 is not benign: loss of function occurs in early RA despite step-up DMARD therapy. Rheumatology, 2010, 49, 1894-1899.	0.9	25
389	Patients with RA in remission on TNF blockers: when and in whom can TNF blocker therapy be stopped?. Annals of the Rheumatic Diseases, 2010, 69, 1636-1642.	0.5	169
390	Pharmacological treatments in rheumatic diseases. , 2010, , 199-209.		1
391	Testing an OMERACT MRI Scoring System for Peripheral Psoriatic Arthritis in Cross-sectional and Longitudinal Settings. Journal of Rheumatology, 2009, 36, 1811-1815.	1.0	29
392	The OMERACT Psoriatic Arthritis Magnetic Resonance Imaging Scoring System (PsAMRIS): Definitions of Key Pathologies, Suggested MRI Sequences, and Preliminary Scoring System for PsA Hands. Journal of Rheumatology, 2009, 36, 1816-1824.	1.0	168
393	Reducing Invasiveness, Duration, and Cost of Magnetic Resonance Imaging in Rheumatoid Arthritis by Omitting Intravenous Contrast Injection — Does It Change the Assessment of Inflammatory and Destructive Joint Changes by the OMERACT RAMRIS?. Journal of Rheumatology, 2009, 36, 1806-1810.	1.0	91
394	The OMERACT Ultrasound Task Force – Advances and Priorities. Journal of Rheumatology, 2009, 36, 2625.1-2625.	1.0	0
395	The OMERACT Ultrasound Task Force — Advances and Priorities. Journal of Rheumatology, 2009, 36, 1829-1832.	1.0	69
396	The OMERACT MRI Inflammatory Arthritis Group: Advances and Future Research Priorities. Journal of Rheumatology, 2009, 36, 1803-1805.	1.0	8

#	Article	IF	Citations
397	Outcome Measurement in Rheumatoid Arthritis: Magnetic Resonance Imaging., 2009,, 275-278.		1
398	Improving recognition of psoriatic arthritis. Practitioner, 2009, 253, 15-8, 2-3.	0.3	3
399	An ultrasonographic study of osteoarthritis of the hand: Synovitis and its relationship to structural pathology and symptoms. Arthritis and Rheumatism, 2008, 59, 1756-1763.	6.7	128
400	How to manage musculoskeletal conditions. Best Practice and Research in Clinical Rheumatology, 2008, 22, 387-394.	1.4	4
401	Care and management of osteoarthritis in adults: summary of NICE guidance. BMJ: British Medical Journal, 2008, 336, 502-503.	2.4	301
402	Hand bone densitometry: a more sensitive standard for the assessment of early bone damage in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2007, 66, 1513-1517.	0.5	41
403	Internal construct validity of the Oxford Knee Scale: Evidence from Rasch measurement. Arthritis and Rheumatism, 2007, 57, 1363-1367.	6.7	57
404	The Rasch measurement model in rheumatology: What is it and why use it? When should it be applied, and what should one look for in a Rasch paper?. Arthritis and Rheumatism, 2007, 57, 1358-1362.	6.7	1,178
405	The OMERACT Ultrasound Group: status of current activities and research directions. Journal of Rheumatology, 2007, 34, 848-51.	1.0	82
406	A multicenter reliability study of extremity-magnetic resonance imaging in the longitudinal evaluation of rheumatoid arthritis. Journal of Rheumatology, 2007, 34, 857-8.	1.0	14
407	Is MRI useful in osteoarthritis?. Best Practice and Research in Clinical Rheumatology, 2006, 20, 57-68.	1.4	15
408	MRI and non-cartilaginous structures in knee osteoarthritis. Osteoarthritis and Cartilage, 2006, 14, 87-94.	0.6	109
409	Examining a whole-organ magnetic resonance imaging scoring system for osteoarthritis of the knee using Rasch analysis. Osteoarthritis and Cartilage, 2006, 14, 116-121.	0.6	29
410	Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: Results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis and Rheumatism, 2005, 52, 27-35.	6.7	521
411	Musculoskeletal ultrasonography: Improving our senses. Arthritis and Rheumatism, 2005, 53, 639-642.	6.7	7
412	Effect of risedronate on joint structure and symptoms of knee osteoarthritis: results of the BRISK randomized, controlled trial [ISRCTN01928173]. Arthritis Research, 2005, 7, R625.	2.0	212
413	Title is missing!. Arthritis Research, 2005, 7, P121.	2.0	О
414	Musculoskeletal ultrasound including definitions for ultrasonographic pathology. Journal of Rheumatology, 2005, 32, 2485-7.	1.0	848

#	Article	IF	Citations
415	Noninvasive techniques for assessing skeletal changes in inflammatory arthritis: imaging technique. Current Opinion in Rheumatology, 2004, 16, 435-442.	2.0	16
416	Elucidation of the relationship between synovitis and bone damage: A randomized magnetic resonance imaging study of individual joints in patients with early rheumatoid arthritis. Arthritis and Rheumatism, 2003, 48, 64-71.	6.7	440
417	OMERACT Rheumatoid Arthritis Magnetic Resonance Imaging Studies. Core set of MRI acquisitions, joint pathology definitions, and the OMERACT RA-MRI scoring system. Journal of Rheumatology, 2003, 30, 1385-6.	1.0	494
418	OMERACT Rheumatoid Arthritis Magnetic Resonance Imaging Studies. Summary of OMERACT 6 MR Imaging Module. Journal of Rheumatology, 2003, 30, 1387-92.	1.0	72
419	The Use of Mri in Elucidating the Pathogenesis of Rheumatoid Arthritis (Ra) and Its Use in Understanding Response to Therapy. Clinical Science, 2002, 103, 35P-35P.	0.0	0
420	Dysregulated lymphocyte proliferation and differentiation in patients with rheumatoid arthritis. Blood, 2002, 100, 4550-4556.	0.6	152
421	Can very high-dose anti-tumor necrosis factor blockade at onset of rheumatoid arthritis produce long-term remission?. Arthritis and Rheumatism, 2002, 46, 1971-1972.	6.7	23
422	How do you diagnose rheumatoid arthritis early?. Best Practice and Research in Clinical Rheumatology, 2001, 15, 49-66.	1.4	17
423	The value of sonography in the detection of bone erosions in patients with rheumatoid arthritis: A comparison with conventional radiography. Arthritis and Rheumatism, 2000, 43, 2762-2770.	6.7	611
424	Flexion contracture is associated with knee joint degeneration on magnetic resonance imaging: data from the Osteoarthritis Initiative. Clinical and Experimental Rheumatology, 0, , .	0.4	2